[ad_1]
Havana, July 17 (RHC) The Cuban biopharmaceutical industry is conducting several research projects, including those aimed at the prevention and treatment of neurodegenerative diseases, cardiovascular diseases and cancer.
Characterized by its closed cycle line of invention and development to production and marketing, the entity works on 422 projects of which 393 are product oriented and 29 technological, all under the 39, aegis of the Biotechnology and Pharmaceutical Industries Group of Cuba (BioCubafarma). 19659003] During a meeting with the press, its director, Eduardo Martínez, explained that one of the megaprojects of the entity is the program of therapeutic molecules for neurodegenerative diseases such as the disease d & # 39; Alzheimer's disease, Parkinson's disease, ataxia and multiple sclerosis. the name of this product developed by the Molecular Immunology Center, one of the 34 companies affiliated with BioCubafar
Another of its main entities, the Center for Genetic Engineering and Biotechnology, is conducting a clinical trial with a cardioprotector that manages to reduce the size of the infarcted area by 78.9 percent.
After five years of foundation, BioCubafarma has among its missions the production of drugs, equipment and services of high technology.
In fact, it produces 62% of the drugs that constitute the basis of essential drugs for dissimilar diseases, consisting of 761 products, 486 of them from the domestic production.
At the same time they place in pharmacies, polyclinics, hospitals and institutes reagents, diagnostic means, equipment, products for stomatological use, among others to ensure human health.
With regard to export, the representative explained that the products reached 34 countries from all latitudes, in r of the implementation of a business model including trade agreements. technology transfer with countries such as Brazil, South Africa, Iran, China and Viet Nam.
Source link
